Background: Pre-clinical and clinical studies have evaluated the efficacy of probiotics in allergy. However, predictive in vitro systems for rational strain selection are still missing. Methods: We developed a novel in vitro screening system for the characterization of probiotics with anti-allergic potential. In this model, human peripheral blood mononuclear cells (PBMC) from healthy donors (n = 68) were skewed towards a Th2 cytokine phenotype by culture with IL-4 and anti-CD40, to resemble cells from allergic donors. Th2-skewed cells were then co-cultured with probiotics; a total of 35 strains were tested. Levels of IFN-γ, IL-10, IL-5 and 7 additional cytokines in culture supernatants were determined by ELISA or multiplex assay. Gene expression was assessed by real-time PCR. For validation, splenocytes from ovalbumin-primed mice and PBMC from grass-allergic donors were restimulated with respective antigen and co-cultured with probiotics, and cytokine profiles were correlated. Results: Culture with IL-4 and anti-CD40 antibody induced secretion of IL-5 from PBMC, indicative of induction of a Th2 phenotype. Cytokine profiles induced by probiotics were strain specific even though species- and genus-specific clustering was observed for many strains by principal component analysis. This was paralleled by mRNA levels of the corresponding genes such as increased Tbet and reduced GATA-3 gene expression. Cytokine profiles induced by probiotics in PBMC stimulated with IL-4 and anti-CD40 correlated with those obtained from allergen-stimulated murine splenocytes or human PBMC from grass-allergic donors. Conclusions: Cytokine profiling of probiotic strains with IL-4-/anti-CD40-stimulated PBMC allowed to determine the effect of probiotics on Th2-skewed cells and thus to classify probiotic strains with anti-allergic potential.

1.
Worldwide variation in prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema: ISAAC. The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee. Lancet 1998;351:1225–1232.
[PubMed]
2.
Kalliomaki M, Salminen S, Arvilommi H, Kero P, Koskinen P, Isolauri E: Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet 2001;357:1076–1079.
[PubMed]
3.
Kukkonen K, Savilahti E, Haahtela T, et al: Probiotics and prebiotic galacto-oligosaccharides in the prevention of allergic diseases: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 2007;119:192–198.
[PubMed]
4.
Abrahamsson TR, Jakobsson T, Bottcher MF, et al: Probiotics in prevention of IgE-associated eczema: a double-blind, randomized, placebo-controlled trial. J Allergy Clin Immunol 2007;119:1174–1180.
[PubMed]
5.
Kim JY, Kwon JH, Ahn SH, et al: Effect of probiotic mix (Bifidobacterium bifidum, Bifidobacterium lactis, Lactobacillus acidophilus) in the primary prevention of eczema: a double-blind, randomized, placebo-controlled trial. Pediatr Allergy Immunol 2010;21:e386–e393.
[PubMed]
6.
Niers L, Martin R, Rijkers G, et al: The effects of selected probiotic strains on the development of eczema (the PandA study). Allergy 2009;64:1349–1358.
[PubMed]
7.
Taylor AL, Dunstan JA, Prescott SL: Probiotic supplementation for the first 6 months of life fails to reduce the risk of atopic dermatitis and increases the risk of allergen sensitization in high-risk children: a randomized controlled trial. J Allergy Clin Immunol 2007;119:184–191.
[PubMed]
8.
Kopp MV, Hennemuth I, Heinzmann A, Urbanek R: Randomized, double-blind, placebo-controlled trial of probiotics for primary prevention: no clinical effects of Lactobacillus GG supplementation. Pediatrics 2008;121:e850–e856.
[PubMed]
9.
Soh SE, Aw M, Gerez I, et al: Probiotic supplementation in the first 6 months of life in at risk Asian infants – effects on eczema and atopic sensitization at the age of 1 year. Clin Exp Allergy 2009;39:571–578.
[PubMed]
10.
Lee J, Seto D, Bielory L: Meta-analysis of clinical trials of probiotics for prevention and treatment of pediatric atopic dermatitis. J Allergy Clin Immunol 2008;121:116–121.
[PubMed]
11.
Viljanen M, Savilahti E, Haahtela T, et al: Probiotics in the treatment of atopic eczema/dermatitis syndrome in infants: a double-blind placebo-controlled trial. Allergy 2005;60:494–500.
[PubMed]
12.
Weston S, Halbert A, Richmond P, Prescott SL: Effects of probiotics on atopic dermatitis: a randomised controlled trial. Arch Dis Child 2005;90:892–897.
[PubMed]
13.
Boyle RJ, Tang ML: The role of probiotics in the management of allergic disease. Clin Exp Allergy 2006;36:568–576.
[PubMed]
14.
Gerasimov SV, Vasjuta VV, Myhovych OO, Bondarchuk LI: Probiotic supplement reduces atopic dermatitis in preschool children: a randomized, double-blind, placebo-controlled, clinical trial. Am J Clin Dermatol 2010;11:351–361.
[PubMed]
15.
Xiao JZ, Kondo S, Yanagisawa N, et al: Probiotics in the treatment of Japanese cedar pollinosis: a double-blind placebo-controlled trial. Clin Exp Allergy 2006;36:1425–1435.
[PubMed]
16.
Peng GC, Hsu CH: The efficacy and safety of heat-killed Lactobacillus paracasei for treatment of perennial allergic rhinitis induced by house-dust mite. Pediatr Allergy Immunol 2005;16:433–438.
[PubMed]
17.
Chen YS, Jan RL, Lin YL, Chen HH, Wang JY: Randomized placebo-controlled trial of lactobacillus on asthmatic children with allergic rhinitis. Pediatr Pulmonol 2010;45:1111–1120.
[PubMed]
18.
Penders J, Stobberingh EE, van den Brandt PA, Thijs C: The role of the intestinal microbiota in the development of atopic disorders. Allergy 2007;62:1223–1236.
[PubMed]
19.
Prescott SL, Bjorksten B: Probiotics for the prevention or treatment of allergic diseases. J Allergy Clin Immunol 2007;120:255–262.
[PubMed]
20.
Kekkonen RA, Kajasto E, Miettinen M, Veckman V, Korpela R, Julkunen I: Probiotic Leuconostoc mesenteroides ssp. cremoris and Streptococcus thermophilus induce IL-12 and IFN-gamma production. World J Gastroenterol 2008;14:1192–1203.
[PubMed]
21.
Niers LE, Timmerman HM, Rijkers GT, et al: Identification of strong interleukin-10 inducing lactic acid bacteria which down-regulate T helper type 2 cytokines. Clin Exp Allergy 2005;35:1481–1489.
[PubMed]
22.
Mohamadzadeh M, Olson S, Kalina WV, et al: Lactobacilli activate human dendritic cells that skew T cells toward T helper 1 polarization. Proc Natl Acad Sci USA 2005;102:2880–2885.
[PubMed]
23.
Foligne B, Nutten S, Grangette C, et al: Correlation between in vitro and in vivo immunomodulatory properties of lactic acid bacteria. World J Gastroenterol 2007;13:236–243.
[PubMed]
24.
Fujiwara D, Inoue S, Wakabayashi H, Fujii T: The anti-allergic effects of lactic acid bacteria are strain dependent and mediated by effects on both Th1/Th2 cytokine expression and balance. Int Arch Allergy Immunol 2004;135:205–215.
[PubMed]
25.
Fujiwara D, Wakabayashi H, Watanabe H, Nishida S, Iino H: A double-blind trial of Lactobacillus paracasei strain KW3110 administration for immunregulation in patients with pollen allergy. Allergol Int 2005;54:143–149.
26.
Vissers YM, Snel J, Zuurendonk PF, Kleerebezem M, Wichers HJ, Savelkoul HF: Lactobacillus strains differentially modulate cytokine production by hPBMC from pollen- allergic patients. FEMS Immunol Med Microbiol 2011;61:28–40.
[PubMed]
27.
Rousset F, Garcia E, Banchereau J: Cytokine-induced proliferation and immunoglobulin production of human B lymphocytes triggered through their CD40 antigen. J Exp Med 1991;173:705–710.
[PubMed]
28.
Yao Y, Li W, Kaplan MH, Chang CH: Interleukin (IL)-4 inhibits IL-10 to promote IL-12 production by dendritic cells. J Exp Med 2005;201:1899–1903.
[PubMed]
29.
Dunstan JA, Hale J, Breckler L, et al: Atopic dermatitis in young children is associated with impaired interleukin-10 and interferon-gamma responses to allergens, vaccines and colonizing skin and gut bacteria. Clin Exp Allergy 2005;35:1309–1317.
[PubMed]
30.
Roessler A, Friedrich U, Vogelsang H, et al: The immune system in healthy adults and patients with atopic dermatitis seems to be affected differently by a probiotic intervention. Clin Exp Allergy 2008;38:93–102.
[PubMed]
31.
Prioult G, Nagler-Anderson C: Mucosal immunity and allergic responses: lack of regulation and/or lack of microbial stimulation? Immunol Rev 2005;206:204–218.
[PubMed]
32.
Smits HH, Engering A, van der KD, et al: Selective probiotic bacteria induce IL-10-producing regulatory T cells in vitro by modulating dendritic cell function through dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin. J Allergy Clin Immunol 2005;115:1260–1267.
[PubMed]
33.
Prescott SL, Wickens K, Westcott L, et al: Supplementation with Lactobacillus rhamnosus or Bifidobacterium lactis probiotics in pregnancy increases cord blood interferon-gamma and breast milk transforming growth factor-beta and immunoglobin A detection. Clin Exp Allergy 2008;38:1606–1614.
[PubMed]
34.
Viljanen M, Pohjavuori E, Haahtela T, et al: Induction of inflammation as a possible mechanism of probiotic effect in atopic eczema-dermatitis syndrome. J Allergy Clin Immunol 2005;115:1254–1259.
[PubMed]
35.
Marschan E, Kuitunen M, Kukkonen K, et al: Probiotics in infancy induce protective immune profiles that are characteristic for chronic low-grade inflammation. Clin Exp Allergy 2008;38:611–618.
[PubMed]
36.
Prescott SL, Dunstan JA, Hale J, et al: Clinical effects of probiotics are associated with increased interferon-gamma responses in very young children with atopic dermatitis. Clin Exp Allergy 2005;35:1557–1564.
[PubMed]
37.
Snel J, Vissers YM, Smit BA, et al: Strain-specific immunomodulatory effects of Lactobacillus plantarum strains on birch-pollen-allergic subjects out of season. Clin Exp Allergy 2011;41:232–242.
[PubMed]
38.
van Wijk F, Wehrens EJ, Nierkens S, et al: CD4+CD25+ T cells regulate the intensity of hypersensitivity responses to peanut, but are not decisive in the induction of oral sensitization. Clin Exp Allergy 2007;37:572–581.
[PubMed]
39.
Wassenberg J, Nutten S, Audran R, et al: Effect of Lactobacillus paracasei ST11 on a nasal provocation test with grass pollen in allergic rhinitis. Clin Exp Allergy 2011;41:565–573.
[PubMed]
40.
Lodinová-Zádníková R, Cukrowska B, Tlaskalova-Hogenova H: Oral administration of probiotic Escherichia coli after birth reduces frequency of allergies and repeated infections later in life (after 10 and 20 years). Int Arch Allergy Immunol 2003;131:209–211.
[PubMed]
You do not currently have access to this content.